Literature DB >> 19491257

A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene.

Gillian G Johnson1, Paul D Sherrington, Anthony Carter, Ke Lin, Triantafillos Liloglou, John K Field, Andrew R Pettitt.   

Abstract

The ATM-p53 pathway plays an important role in the biology of chronic lymphocytic leukemia (CLL). Its functional integrity can be probed by exposing CLL cells to ionizing radiation (IR) and measuring levels of p53 protein and one of its transcriptional targets, the cyclin-dependent kinase inhibitor p21. We have previously identified two abnormal p53/p21 response patterns associated with inactivating mutations of TP53 and ATM, respectively. Here, we describe a third abnormal response pattern characterized by failure of p21 protein accumulation despite a normal p53 protein response. This so-called "type C" response was detected in 10.6% of unselected patients and was associated with resistance of CLL cells to p53-dependent killing by IR, with the clinically more aggressive variant of CLL characterized by unmutated immunoglobulin heavy-chain genes and with a single nucleotide polymorphism at codon 31 of the p21 gene in which Ser is replaced by Arg. CLL samples with this allelic variant displayed impaired IR-induced up-regulation of total p21 mRNA and did not express the Arg-encoding transcript, except in those cases harboring an additional single nucleotide polymorphism (T instead of C) in the 3'-untranslated region of the same p21 allele. Our data provide new insight into the importance of p21 in CLL biology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491257     DOI: 10.1158/0008-5472.CAN-09-0627

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 2.  The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.

Authors:  Cheng Wang; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

3.  The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells.

Authors:  Lela Kardava; Qi Yang; Anthony St Leger; Kenneth A Foon; Suzanne Lentzsch; Abbe N Vallejo; Christine Milcarek; Lisa Borghesi
Journal:  Int Immunol       Date:  2011-05-06       Impact factor: 4.823

Review 4.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

5.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 6.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

7.  Roles of CDKN1A gene polymorphisms (rs1801270 and rs1059234) in the development of cervical neoplasia.

Authors:  Sandra Liliana Vargas-Torres; Elyzabeth Avvad Portari; Amanda Lima Silva; Evandro Mendes Klumb; Heloísa Carneiro da Rocha Guillobel; Maria José de Camargo; Cíntia Barros Santos-Rebouças; Fábio Bastos Russomano; Jacyara Maria Brito Macedo
Journal:  Tumour Biol       Date:  2016-02-05

8.  Heterogeneity of p53-pathway Protein Expression in Chemosensitive Chronic Lymphocytic Leukemia: A Pilot Study.

Authors:  Michael J Groves; Stephanie F Maccallum; Michael T Boylan; Sally Haydock; Joan Cunningham; Keith Gelly; Duncan Gowans; Ron Kerr; Philip J Coates; Sudhir Tauro
Journal:  J Cancer       Date:  2012-08-24       Impact factor: 4.207

9.  HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Authors:  Angela M Sosin; Angelika M Burger; Aisha Siddiqi; Judith Abrams; Ramzi M Mohammad; Ayad M Al-Katib
Journal:  J Hematol Oncol       Date:  2012-09-18       Impact factor: 17.388

10.  Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.

Authors:  G D te Raa; P D Moerland; A C Leeksma; I A Derks; H Yigittop; N Laddach; M Loden-van Straaten; V Navrkalova; M Trbusek; D M Luijks; T Zenz; A Skowronska; M Hoogendoorn; T Stankovic; M H van Oers; E Eldering; A P Kater
Journal:  Cell Death Dis       Date:  2015-08-06       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.